chlamydia

Hologic this week reported a 3 percent year-over-year decline in fiscal first-quarter revenues, including a 7 percent drop in revenues in its Diagnostics division.

A team from Estonia's University of Tartu and molecular diagnostics startup Selfdiagnostics has published a peer-reviewed study describing and clinically validating a recently developed point-of-care molecular assay to diagnose chlamydia infections.

Cepheid's Xpert CT/NG assay for the detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae, launched in the US at the start of the year, has seen the greatest uptake of any new Xpert test since Xpert MRSA, President and CEO John Bishop

Cepheid's Xpert CT/NG assay for detecting Chlamydia trahcomatis and Neisseria gonorrhoeae is at least as accurate as two other commercially available molecular tests for the bacteria, according to the recently published results of the beta phase of a multi-center clinical

This article has been updated from a previous version to clarify the current test menu for BD's platforms.

Scientists from Network Biosystems have published research demonstrating that the company's rapid, point-of-care system for diagnosing and differentiating Chlamydia trachomatis strains achieved greater sensitivity and specificity than a commercially available PCR-based

Cepheid said last week that it has received clearance from the US Food and Drug Administration to market Xpert CT/NG on its GeneXpert system.